An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Latest Information Update: 02 Feb 2025
Price :
$35 *
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions
- Acronyms roMyG
- Sponsors UCB
- 25 Jun 2024 Status changed from not yet recruiting to recruiting.
- 10 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 15 May 2024.
- 09 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Mar 2024.